Salivary Glucose Levels Measured by Biochip Sensor
|
By LabMedica International staff writers Posted on 18 Jun 2014 |

Image: The schematic shows glucose molecules sliding along the biochip sensor surface illuminated by different colors. Change in light intensity transmitted through the slits of each plasmonic interferometer can be used to measure the glucose concentration in saliva (Photo courtesy of Domenico Pacifici, PhD).
A new biochip sensor has been developed that can selectively measure concentrations of glucose in a complex solution similar to human saliva.
The new chip makes use of a series of specific chemical reactions combined with plasmonic interferometry which is a means of detecting chemical signature of compounds using light. The device is sensitive enough to detect differences in glucose concentrations that amount to just a few thousand molecules in the sampled volume.
Scientists at Brown University (Providence, RI, USA) exploited the synergistic advantage of combining plasmonic interferometry with an enzyme-driven dye assay that yields an optical sensor capable of detecting glucose in saliva with high sensitivity and selectivity. The biochip is made from a 2.54 x 2.54-cm piece of quartz coated with a thin layer of silver. Etched in the silver are thousands of nanoscale interferometers, tiny slits with a groove on each side. The grooves measure 200 nm wide and the slit is 100 nm wide.
When a liquid is deposited on the chip, the light and the surface plasmon waves propagate through that liquid before they interfere with each other. That alters the interference patterns picked up by the detectors, depending on the chemical makeup of the liquid. The scientists added microfluidic channels to the chip to introduce two enzymes that react with glucose in a very specific way. The first enzyme, glucose oxidase, reacts with glucose to form a molecule of hydrogen peroxide. This molecule then reacts with the second enzyme, horseradish peroxidase, to generate a molecule called resorufin, which can absorb and emit red light, thus coloring the solution. The team could then tune the interferometers to look for the red resorufin molecules.
The team tested its combination of dye chemistry and plasmonic interferometry by looking for glucose in artificial saliva, a mixture of water, salts and enzymes that resembles the real human saliva. They found that they could detect resorufin in real time with great accuracy and specificity. They were able to detect changes in glucose concentration of 0.1 μM/L, which is 10 times the sensitivity that can be achieved by interferometers alone. The proposed device is highly sensitive and highly specific for glucose sensing in picoliter volumes, across the physiological range of glucose concentrations found in human saliva, which is 20 μM–240 μM.
Domenico Pacifici, PhD, an assistant professor of engineering, and who led the study, said, “We have demonstrated the sensitivity needed to measure glucose concentrations typical in saliva, which are typically 100 times lower than in blood. Now we are able to do this with extremely high specificity, which means that we can differentiate glucose from the background components of saliva.” The study was published in the June 2014 edition of the journal Nanophotonics.
Related Links:
Brown University
The new chip makes use of a series of specific chemical reactions combined with plasmonic interferometry which is a means of detecting chemical signature of compounds using light. The device is sensitive enough to detect differences in glucose concentrations that amount to just a few thousand molecules in the sampled volume.
Scientists at Brown University (Providence, RI, USA) exploited the synergistic advantage of combining plasmonic interferometry with an enzyme-driven dye assay that yields an optical sensor capable of detecting glucose in saliva with high sensitivity and selectivity. The biochip is made from a 2.54 x 2.54-cm piece of quartz coated with a thin layer of silver. Etched in the silver are thousands of nanoscale interferometers, tiny slits with a groove on each side. The grooves measure 200 nm wide and the slit is 100 nm wide.
When a liquid is deposited on the chip, the light and the surface plasmon waves propagate through that liquid before they interfere with each other. That alters the interference patterns picked up by the detectors, depending on the chemical makeup of the liquid. The scientists added microfluidic channels to the chip to introduce two enzymes that react with glucose in a very specific way. The first enzyme, glucose oxidase, reacts with glucose to form a molecule of hydrogen peroxide. This molecule then reacts with the second enzyme, horseradish peroxidase, to generate a molecule called resorufin, which can absorb and emit red light, thus coloring the solution. The team could then tune the interferometers to look for the red resorufin molecules.
The team tested its combination of dye chemistry and plasmonic interferometry by looking for glucose in artificial saliva, a mixture of water, salts and enzymes that resembles the real human saliva. They found that they could detect resorufin in real time with great accuracy and specificity. They were able to detect changes in glucose concentration of 0.1 μM/L, which is 10 times the sensitivity that can be achieved by interferometers alone. The proposed device is highly sensitive and highly specific for glucose sensing in picoliter volumes, across the physiological range of glucose concentrations found in human saliva, which is 20 μM–240 μM.
Domenico Pacifici, PhD, an assistant professor of engineering, and who led the study, said, “We have demonstrated the sensitivity needed to measure glucose concentrations typical in saliva, which are typically 100 times lower than in blood. Now we are able to do this with extremely high specificity, which means that we can differentiate glucose from the background components of saliva.” The study was published in the June 2014 edition of the journal Nanophotonics.
Related Links:
Brown University
Latest Clinical Chem. News
- Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
- Daily Blood Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
- Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis
- Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
- Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
- Study Links Saliva-Based Epigenetic Signals to OCD Treatment Outcomes
- New One-Step Syphilis Test Could Enable Earlier Detection and Faster Treatment
- Multimodal Clinical Data Models Predict Cachexia Risk Across Cancers
- Study Evaluates Alzheimer’s Blood Biomarker Across Racial and Ethnic Groups
- Blood Protein May Help Identify Treatment-Resistant Psychosis
- Electrochemical Biosensor Rapidly Detects Cerebrospinal Fluid Leaks
- Blood Protein Panel Supports Monitoring of Treated Celiac Disease
- Hemoglobin Levels May Help Signal Long-Term Dementia Risk
- Liquid Biopsy Platform Shows Promise for Early Gynecologic Cancer Detection
- Global Survey Finds Pediatric Troponin Testing Lacks Consistent Reference Intervals
- Multi-Omics Study Identifies Blood Marker for MASLD Progression
Channels
Molecular Diagnostics
view channel
Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use
Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more
AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. Identifying these patients earlier could reduce the costs of ineffective... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read moreLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read moreIndustry
view channel
Qiagen Agrees to Go Private Through EQT-Led Acquisition
QIAGEN N.V. (Venlo, the Netherlands) and EQT Private Equity (Stockholm, Sweden) have agreed to an all-cash public takeover offer for all outstanding QIAGEN shares at EUR 46.50 per share.... Read more
Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
Hologic, Inc. (Marlborough, MA, USA) and Inpeco S.A. (Novazzano, Switzerland) have signed a co-marketing partnership in Europe for Inpeco’s recently launched FlexLab X automation solution and Hologic’s... Read more







